靶向IGSF9的治疗抑制急性髓系白血病的进展
研究揭示干扰素γ(IFN-γ)通过JAK1/STAT1通路诱导急性髓系白血病(AML)细胞表达IGSF9与PD-L1,IGSF9促进肿瘤免疫逃逸并介导髓外浸润。作者开发靶向IGSF9的抗体药物偶联物(anti-IGSF9-linker-DXd),在体外和体内均显示抗AML活性。
要点
- IFN-γ通过JAK1/STAT1通路诱导AML细胞表达IGSF9与PD-L1。
- IGSF9促进肿瘤免疫逃逸并介导AML细胞髓外浸润。
- anti-IGSF9-linker-DXd在体内几乎完全消除早中期肿瘤。
核心结论
- IGSF9是AML治疗的新靶点,靶向IGSF9的抗体药物偶联物在体内外均显示抗AML疗效。
研究设计与样本
- 基础与临床前研究,包括体外细胞实验和体内动物实验,未报告样本量。
主要发现
- IFN-γ诱导AML细胞表达IGSF9,靶向JAK1的小干扰RNA和STAT1抑制剂阻断IFN-γ信号通路后显著抑制IGSF9和PD-L1表达。
- IGSF9作为肿瘤特异性免疫检查点分子促进肿瘤逃逸,并介导AML细胞髓外浸润,消耗IGSF9或抗IGSF9可抑制髓外浸润。
- 抗IGSF9的结合表位位于IGSF9的免疫球蛋白G2和纤连蛋白III型结构域2内。
- anti-IGSF9-linker-DXd纯度为99.7%,主要以单体形式存在,药物抗体比为8-10,具有特异性和旁观者效应。
- 体内实验中,anti-IGSF9-linker-DXd几乎完全消除早中期肿瘤,并显著抑制晚期肿瘤进展。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previously, we reported that targeting immunoglobulin superfamily member 9 (IGSF9) could enhance antitumor T-cell activity and sensitivity to anti-PD-1 immunotherapy, although the detailed mechanism remains unclear. In this study, we find that, similar to the regulation of PD-L1 expression, interferon gamma (IFN-γ) also induces the expression of IGSF9 in acute myeloid leukemia (AML). The small interfering RNA specifically targeting JAK1 and a STAT1 inhibitor blocking IFN-γ signal pathway significantly inhibit the expression of IGSF9 and PD-L1. As a tumor-specific immune checkpoint molecule, IGSF9 plays a significant role in promoting tumor escape. The induction of both PD-L1 and IGSF9 by IFN-γ in the tumor microenvironment explains why IGSF9 is highly expressed in tumors and tumor-infiltrating immune cells. This induction also underpins the strong synergistic effects when combining anti-IGSF9 and anti-PD-1 therapies. Additionally, IGSF9 also mediates the extramedullary infiltration of AML cells, which can be inhibited by depletion of IGSF9 or anti-IGSF9. The binding epitopes of anti-IGSF9 are located within the immunoglobulin G2 and fibronectin type-III-2 domains of IGSF9. Based on these findings, we develop an antibody-drug conjugate (ADC) targeting IGSF9 (anti-IGSF9-linker-DXd). This ADC exhibits 99.7% purity, and primarily exists in monomeric form, demonstrating excellent homogeneity (drug-to-antibody ratio, 8-10) and specificity. Anti-IGSF9-linker-DXd effectively kills IGSF9-positive tumor cells and exhibits a potent bystander effect. In vivo, anti-IGSF9-linker-DXd almost completely eliminates early- and mid-stage tumors and significantly inhibits the progression of advanced tumors. In summary, our findings underscore the potential of IGSF9 as a novel therapeutic target for AML treatment, highlighting its role in disease progression and the efficacy of targeted therapies.
引用
- Hui L, Xiao J, Zhao Z, et al. IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia. Blood Adv. 2025. PMID: 40526840. doi:10.1182/bloodadvances.2025016432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。